| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | -0.074 | 0.07 |
| mRNA | TG-100-115 | CTRPv2 | pan-cancer | AAC | -0.072 | 0.08 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.12 | 0.08 |
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | 0.086 | 0.08 |
| mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | -0.083 | 0.08 |
| mRNA | RITA | CTRPv2 | pan-cancer | AAC | 0.07 | 0.08 |
| mRNA | PLX4720 | CTRPv2 | pan-cancer | AAC | -0.068 | 0.08 |
| mRNA | VAF-347 | CTRPv2 | pan-cancer | AAC | 0.088 | 0.08 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.072 | 0.08 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.072 | 0.08 |